Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
May 21, 2001
- Santen Ties Up with PDI for Levofloxacin
May 21, 2001
- JMA to Start Monitoring Medical Facilities' Business Performance
May 21, 2001
- SSP, Nihon Tenganyaku to Jointly Research Antifungal Eye Drop
May 21, 2001
- \240,000 Necessary per Month forNursing Care: Survey Respondents
May 21, 2001
- Kissei Completes Therapeutic Nutritive Food Business Center
May 21, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2001
- Ethical Drugs Achieve 2.5% Growth in FY2000
May 21, 2001
- WORLD NEWS ON BRIEF
May 21, 2001
- Sankyo Stresses Fewer Drug Interactions for Mevalotin
May 21, 2001
- Sanofi-Synthelabo, Organon to Jointly Start PII for Pentasaccharide
May 21, 2001
- JPMA to Hold Int'l Panel Focusing on Patient-Oriented Healthcare
May 14, 2001
- Evidence on Acute Myocardial Infarctions in Japan Compiled by Korosho Study Group
May 14, 2001
- Wholesalers' FTC to Stop Members Supporting Medical Institution Social Gatherings
May 14, 2001
- Diagnostic, Treatment GL for Urinary Incontinence in Women Prepared
May 14, 2001
- BUSINESS NEWS IN BRIEF -2-
May 14, 2001
- Health Insurance Coverage for Viagra Demanded by the Public: Pfizer Seminar
May 14, 2001
- Kyowa Hakko Kogyo Aims at \300 Bil. Drug Sales in 2011: President Hirata
May 14, 2001
- 2hPG Recommended for Predicting Cardiovascular Disease Mortality: Takeda Seminar
May 14, 2001
- NBI to Increase Its Sales to \110 Bil. in 2004: President Kawabata
May 14, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…